Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,568Revenue $M576Net Margin (%)-11.7Z-Score12.8
Enterprise Value $M10,355EPS $0.2Operating Margin %-12.9F-Score6
P/E(ttm))0Cash Flow Per Share $0.0Pre-tax Margin (%)-10.7Higher ROA y-yN
Price/Book7.910-y EBITDA Growth Rate %0Quick Ratio6.9Cash flow > EarningsY
Price/Sales24.15-y EBITDA Growth Rate %0Current Ratio7.4Lower Leverage y-yY
Price/Cash Flow725y-y EBITDA Growth Rate %-68.3ROA % (ttm)-4.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-5.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M146ROI % (ttm)-2.4Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 72.1961%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 72.1957%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 72.1957%New holding, 55309 sh.55,309
ALKSJohn Burbank 2014-06-30 Sold Out -0.01%$41.1 - $50.94
($46.06)
$ 72.1957%Sold Out0
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 72.1953%Add 41.07%5,180,238
ALKSJohn Burbank 2014-03-31 Buy 0.01%$40.07 - $53.82
($47.41)
$ 72.1952%New holding, 4651 sh.4,651
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 72.1996%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 72.19122%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 72.19122%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 72.19148%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 72.19148%New holding, 26624 sh.26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 72.19230%Add 47.24%1,233,024
ALKSVanguard Health Care Fund 2012-03-31 Buy 0.07%$16.14 - $19.5
($16.48)
$ 72.19338%New holding, 787900 sh.787,900
ALKSJohn Burbank 2012-03-31 Sold Out -0.23%$16.14 - $19.5
($16.48)
$ 72.19338%Sold Out0
ALKSDaniel Loeb 2010-06-30 Sold Out -0.92%$10.7 - $13.75
($12.33)
$ 72.19486%Sold Out0
ALKSDaniel Loeb 2010-03-31 Buy 0.92%$9.41 - $14.01
($11.62)
$ 72.19521%New holding, 1000000 sh.1,000,000
ALKSGeorge Soros 2010-03-31 Sold Out $9.41 - $14.01
($11.62)
$ 72.19521%Sold Out0
ALKSJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.41 - $14.01
($11.62)
$ 72.19521%Sold Out0
ALKSGeorge Soros 2009-12-31 Buy $7.58 - $9.88
($8.72)
$ 72.19728%New holding, 22800 sh.22,800
ALKSDaniel Loeb 2009-12-31 Sold Out -0.37%$7.58 - $9.88
($8.72)
$ 72.19728%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALKS Ken Fisher 2014-12-31107,1640.070.01+10.18%
ALKS Vanguard Health Care Fund 2014-12-316,226,3834.260.86+0.05%
ALKS Ken Fisher 2014-09-3097,2640.070.01+75.86%
ALKS Vanguard Health Care Fund 2014-09-306,223,0834.260.68+1.42%
Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2015-01-26Sell15,000$70.023.21view
Cooke ShanePresident, Alkermes plc 2015-01-23Sell118,000$69.134.54view
BLOOM FLOYD EDirector 2015-01-16Sell20,000$67.127.67view
FRATES JAMES MSVP & CFO, Alkermes plc 2015-01-15Sell10,000$66.868.09view
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc. 2015-01-15Sell18,375$66.458.76view
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc. 2015-01-07Sell28,374$6511.18view
BREYER ROBERT ADirector 2015-01-02Sell5,000$58.5723.39view
POPS RICHARD FDirector and CEO, Alkermes plc 2014-12-11Sell100,000$56.0428.96view
FRATES JAMES MSVP & CFO, Alkermes plc 2014-12-10Sell18,870$56.0728.89view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2014-12-09Sell18,000$56.8227.19view

Press Releases about ALKS :

    Quarterly/Annual Reports about ALKS:

    News about ALKS:

    Articles On GuruFocus.com
    wait for positive ea Apr 06 2013 
    comment on ALKS Mar 09 2013 
    Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
    Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
    Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
    Opportunistic Coat-tailing Jan 05 2010 

    More From Other Websites
    Cramer: Wouldn't you rather own a winner than a whiner? Jan 27 2015
    Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Jan 19 2015
    Why Citigroup Placed An $85 Price Target On Shares Of Alkermes Jan 14 2015
    Schizophrenia breakthrough? Jan 07 2015
    Alkermes stock surges after schizophrenia drug shows effectiveness without weight gain Jan 07 2015
    Jim Cramer Says Alkermes Shares Are Going 'Much Higher' Jan 07 2015
    Alkermes Hits High On Schizophrenia Drug Results Jan 07 2015
    Alkermes CEO: Our Proprietary Drug Pipeline is 'Maturing Beautifully' Jan 07 2015
    Cramer's Stop Trading: 'Holy Grail' drug Jan 07 2015
    [$$] Alkermes Schizophrenia Drug Shows Less Weight Gain Jan 07 2015
    Alkermes shares up 5% on news of positive trial for schizophrenia drug Jan 07 2015
    Alkermes schizophrenia drug meets main goal in mid-stage trial Jan 07 2015
    BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Eli Lilly, Kalobios, Zafgen Jan 07 2015
    Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Jan 07 2015
    Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Jan 07 2015
    Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Jan 07 2015
    Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare... Jan 06 2015
    Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare... Jan 06 2015
    Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare... Jan 06 2015
    Midday movers: Chevron, Hess, Morgan Stanley & more Jan 06 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK